Empliciti (elotuzumab) / AbbVie, BMS 
Welcome,         Profile    Billing    Logout  

43 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Empliciti (elotuzumab) / AbbVie, BMS
ACTRN12616001030460: A Multicentre Phase 3 Trial Comparing Elotuzumab-Cyclophosphamide-Thalidomide-Dexamethasone (E-CTD) with Cyclophosphamide-Thalidomide-Dexamethasone (CTD) for the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
300
 
Australasian Leukaemia and Lymphoma Group (ALLG), Bristol-Myers Squibb
Multiple Myeloma
 
 
2014-003079-40: Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment Studie für Patienten mit zuvor unbehandeltem Multiplem Myelom zur Untersuchung der Wirksamkeit von Elotuzumab im Rahmen einer Induktions- und Konsolidierungstherapie mit Bortezomib/Lenalidomid/Dexamethason sowie in der Erhaltungstherapie mit Lenalidomid

Completed
3
564
Europe
Lenalidomide, Elotuzumab, CC-5013, BMS-901608, formerly known as HuLuc63, Capsule, hard, Powder for solution for infusion, Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 25 mg, Empliciti, Revlimid 10mg
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg, Celgene International Sarl, Bristol-Myers Squibb International Corporation, Chugai
Newly diagnosed symptomatic multiple myeloma symptomatisches Multiples Myelom, Primärtherapie, symptomatic, newly diagnosed (previously untreated) multiple myeloma bisher unbehandeltes, symptomatisches Multiples Myelom, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-001005-67: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy Allogene Stammzelltransplantation im Vergleich zur konventionellen Therapie als Salvage-Therapie für Patienten mit rezidiviertem / progredientem Multiplem Myelom nach der Erstlinientherapie

Not yet recruiting
3
482
Europe
human allogeneic hematopoietic stem cells from peripheral blood stem cell collections, human autologous stem cells, DARZALEX® 20 mg/ml, Suspension for injection, Powder and solvent for concentrate for solution for infusion, Solution for injection, Capsule, hard, Concentrate and solvent for solution for infusion, , Powder for solution for injection, Powder for injection, Tablet, human allogeneic hematopoietic stem cells (allo-HSC) from peripheral blood stem cell (PBSC) collections, autologous stem cells, Kyprolis®, DARZALEX® 1 800 mg Injektionslösung, NINLARO®, Empliciti®, IMNOVID, DARZALEX® 20 mg/ml, REVLIMID® Hartkapseln, VELCADE 3,5 mg Pulver, Bortezomib medac 3,5 mg, Fortecortin® Inject, Fortecortin®
University Medical Center Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA)
Multiple myeloma, cancer that forms in a type of white blood cell called a plasma cell, Diseases [C] - Cancer [C04]
 
 
MonumenTAL-6, NCT06208150: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Recruiting
3
795
Europe, Canada, Japan, US, RoW
Talquetamab, JNJ-64407564, Talvey, Pomalidomide, Pomalyst, Imnovid, Teclistamab, JNJ-64007957, Tecvayli, Elotuzumab, Empliciti, Dexamethasone, Bortezomib, Velcade
Janssen Research & Development, LLC
Multiple Myeloma
04/26
03/28
MagnetisMM-32, NCT06152575: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Recruiting
3
492
Europe, Canada, Japan, US, RoW
Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Pfizer
Multiple Myeloma
08/26
12/27
ALUMMINATE, NCT06232707: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn
3
466
Europe, Canada, Japan, US, RoW
Alnuctamab, BMS-986349, CC-93269, Pomalidomide, POMALYST®, IMNOVID®, CC-4047, BMS-986379, Daratumumab, DARZALEX®, DARZALEX, FASPRO®, Elotuzumab, Empliciti®, BMS-901608, Carfilzomib, KYPROLIS®, Dexamethasone
Celgene
Multiple Myeloma
11/25
09/30
NCT06158841: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, Canada, Japan, US, RoW
Etentamig, ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
12/27
XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : H2'24 - Market entry in Malaysia in combination with bortezomib and dexamethasone for r/r MM
Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Active, not recruiting
3
117
Europe
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
European Myeloma Network B.V., Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Oct 2022 - Dec 2023: Approval in US for 3-5L multiple myeloma
Hourglass Jun 2023 - Jun 2023 : Subgroup analysis of outcomes for patients with high-risk r/r multiple myeloma from the KarMMa-3 trial at EHA 2023
Checkmark Data from KarMMa-3 trial for 3L multiple myeloma
Aug 2022 - Aug 2022: Data from KarMMa-3 trial for 3L multiple myeloma
Active, not recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
04/27
04/27
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Terminated
3
28
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/25
03/25
DSMM XVII, NCT03948035 / 2017-001616-11: Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Active, not recruiting
3
576
Europe
Elotuzumab, Empliciti®, Carfilzomib, Kyprolis®, Lenalidomide, Revlimid®, Dexamethasone, Fortecortin®, autologous stem cell transplant
Wuerzburg University Hospital, ClinAssess GmbH, Arbeitsgemeinschaft medikamentoese Tumortherapie
Newly Diagnosed Multiple Myeloma
08/29
08/29
LINKER-MM3, NCT05730036: A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
3
410
Europe, Canada, Japan, US, RoW
Linvoseltamab, REGN5458, Lynozyfic™, Elotuzumab, Empliciti, Pomalidomide, Pomalyst, Dexamethasone, Decadron
Regeneron Pharmaceuticals
Relapsed Refractory Multiple Myeloma (RRMM)
04/33
04/33
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Completed
2
51
US
Elotuzumab, HuLuc63, Lenalidomide, REVLIMID, Dexamethasone, Decadron
Dana-Farber Cancer Institute, Bristol-Myers Squibb, Celgene, Blood Cancer Research Partnership, Multiple Myeloma Research Consortium, The Leukemia and Lymphoma Society
Smoldering Myeloma, Smoldering Multiple Myeloma
12/18
01/22
Elo-KRd, NCT03361306: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Completed
2
15
US
Elotuzumab, Empliciti
Wake Forest University Health Sciences, Bristol-Myers Squibb, Atrium Health Levine Cancer Institute
Multiple Myeloma
06/21
02/25
NCT02375555: Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Completed
2
40
US
Lenalidomide, Revlimid®, Elotuzumab, HuLuc63, Bortezomib, Velcade, Dexamethasone, Baycadron Elixer, Decadron, Stem Cell Mobilization
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma
12/21
01/24
NCT02718833: A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Active, not recruiting
2
52
US
Elotuzumab, Empliciti, Pomalidomide, Pomalyst, Bortezomib, Velcade, Dexamethasone, Decadron
Massachusetts General Hospital, Celgene, Bristol-Myers Squibb, Multiple Myeloma Research Consortium
Multiple Myeloma
12/26
12/27
CA204-225, NCT03030261: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Active, not recruiting
2
25
Canada, US
Elotuzumab, Empliciti, Pomalidomide, Pomalyst, Dexamethasone, Decadron
Washington University School of Medicine, Bristol-Myers Squibb, Celgene
Multiple Myeloma in Relapse
09/22
09/27
NCT03155100 / 2016-001178-13: Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

Completed
2
15
Europe
Carfilzomib for Inj 60 milligram (MG), Proteasome inhibitor, Elotuzumab 400 MG, Monoclonal antibody, Dexamethasone, Steroid
Raija Silvennoinen, Amgen, Bristol-Myers Squibb, Hospital District of Helsinki and Uusimaa
Multiple Myeloma in Relapse
08/23
08/23
NCT03252600: Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Active, not recruiting
2
53
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Pharmacological Study
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI), Bristol-Myers Squibb, Multiple Myeloma Research Consortium
Recurrent Primary Amyloidosis
12/23
12/23
CA204-185, NCT02719613 / 2016-000037-51: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Active, not recruiting
2
67
Europe, Canada, Japan, US, RoW
Elotuzumab, BMS-901608, HuLuc63, Empliciti, Dexamethasone, Lenalidomide, Revlimid®, Bortezomib, Velcade®, Pomalidomide, Pomalyst ®, Nivolumab, Opdivo ®
Bristol-Myers Squibb, AbbVie
Multiple Myeloma
11/25
11/25
IMPEDE, NCT04835129: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma

Recruiting
2
53
US
Isatuximab (for run-in portion), Sarclisa, SAR-650984, isatuximab-irfc, Isatuximab (for expansion), Pomalidomide, Pomalyst, Imnovid, Elotuzumab, Empliciti, HuLuc63, Dexamethasone, Baycadron, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Medical College of Wisconsin
Multiple Myeloma
01/26
01/27
NCT02420860: Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
113
US
Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
04/27
04/27
RV-MM-PI-0691, NCT01729091: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed
2
72
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Cell Transplantation, autologous stem cell transplantation, Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Plasma Cell Leukemia, Plasma Cell Myeloma
06/24
06/24
NCT03713294: Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Completed
2
37
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
Mayo Clinic, National Cancer Institute (NCI)
Refractory Plasma Cell Myeloma
02/24
11/24
NCT04517851: Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Active, not recruiting
2
15
US
Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Questionnaire Administration
M.D. Anderson Cancer Center
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
12/27
12/27
Elo-KRd, NCT02969837: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Completed
2
46
US
Elotuzumab, Empliciti, Carfilzomib, Kryprolis, Lenalidomide, Revlimid, Dexamethasone
University of Chicago, Bristol-Myers Squibb, Amgen, Multiple Myeloma Research Foundation
Multiple Myeloma
10/21
12/25
NCT04918147: Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Terminated
2
8
US
elotuzumab, BMS-901608, Empliciti®, placebo for elotuzumab, normal saline, methylprednisolone, Solu-Medrol®, diphenhydramine, Benadryl®, acetaminophen, Tylenol®, famotidine, H2 blocker, prednisone, corticosteroid
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Bristol-Myers Squibb, Rho Federal Systems Division, Inc.
IgG4 Related Disease, IgG4-RD
01/24
01/24
SWOG-1211, NCT01668719: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Active, not recruiting
1/2
142
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Elotuzumab, BMS-901608, HuLuc63, PDL-063, PDL063, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
SWOG Cancer Research Network, National Cancer Institute (NCI)
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
02/20
12/25
NCT05002816: Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Recruiting
1/2
24
US
Elotuzumab, Belantamab mafodotin
Yale University, GlaxoSmithKline
Multiple Myeloma
01/26
12/26
NCT04065425: Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Not yet recruiting
1/2
104
NA
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone, BMS-986016, Anti LAG-3, Relatlimab, Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone, BMS-986207, Anti TIGIT
Multiple Myeloma Research Consortium, Bristol-Myers Squibb
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
10/23
10/23
CC-92480-MM-002, NCT03989414 / 2018-004767-31: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting
1/2
424
Europe, Canada, US, RoW
CC-92480, BMS-986348, mezigdomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
Celgene
Multiple Myeloma
11/26
11/26
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Terminated
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
08/24
08/24
NCT06518551: Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Recruiting
1/2
49
US
Elotuzumab, BMS-901608, Iberdomide, CC-220, Iberdomide hydrochloride, C25H28N3O5Cl, BMS-986382, Dexamethasone, Decadron, 9- fluoro11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione
Omar Nadeem, MD, Celgene, Bristol-Myers Squibb
Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
12/29
12/34
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
NCT06785415: Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Recruiting
1/2
37
US
Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Scan, Bone Scintigraphy, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Daratumumab, Daratumumab Biosimilar HLX15, Daratumumab-fihj, Darzalex, HLX15, HuMax-CD38, JNJ 54767414, JNJ-54767414, JNJ54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Elotuzumab, BMS 901608, BMS-901608, BMS901608, Empliciti, HuLuc-63, HuLuc63, PDL 063, PDL-063, PDL063, Iberdomide, CC 220, CC-220, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Mayo Clinic
Recurrent Multiple Myeloma
04/31
04/31
NCT04614636: FT538 in Subjects With Advanced Hematologic Malignancies

Terminated
1
42
US
FT538, Cyclophosphamide, Fludarabine, Daratumumab, Darzalex, Elotuzumab, Empliciti
Fate Therapeutics
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
07/23
08/23
CC-220, NCT05560399: A Study of Iberdomide () in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
7
US
Iberdomide, CC-220, Elotuzumab, Dexamethasone
Icahn School of Medicine at Mount Sinai, Multiple Myeloma Research Consortium, Bristol-Myers Squibb
Multiple Myeloma
11/26
12/26
NCT05981209: Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Recruiting
1
27
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Echocardiography, EC, Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Mezigdomide, BMS 986348, BMS-986348, BMS986348, CC 92480, CC-92480, CELMoD CC-92480, Cereblon E3 Ligase Modulation Drug CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon Modulator CC-92480, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
Abdullah Khan
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
12/26
12/26
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

No Longer Available
N/A
US
Elotuzumab, BMS-901608
Sundar Jagannath, Bristol-Myers Squibb
Multiple Myeloma
 
 
NCT03126617: Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

No Longer Available
N/A
NA
Elotuzumab, Empliciti, BMS-901608
Bristol-Myers Squibb
Multiple Myeloma
 
 
NCT02856438: Early Patient Access Treatment Use Protocol CA204-220

No Longer Available
N/A
Japan
Elotuzumab, BMS-901608, Lenalidomide, Dexamethasone
Bristol-Myers Squibb, AbbVie
Multiple Myeloma
 
 
NCT02368301: Expanded Access Treatment Protocol CA204-143

No Longer Available
N/A
NA
Elotuzumab in combination with Lenalidomide and Dexamethasone
Bristol-Myers Squibb
Multiple Myeloma
 
 
CA204-219, NCT06163040: A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed
N/A
7
RoW
Elotuzumab in combination with pomalidomide and dexamethasone, Elotuzumab in combination with lenalidomide and dexamethasone
Bristol-Myers Squibb
Relapsed or Refractory Multiple Myeloma
03/25
03/25

Download Options